Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Non-Current Liabilities (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $46.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 70.6% year-over-year to $46.6 million, compared with a TTM value of $46.6 million through Sep 2025, down 70.6%, and an annual FY2024 reading of $116.9 million, down 52.36% over the prior year.
  • Total Non-Current Liabilities was $46.6 million for Q3 2025 at CytomX Therapeutics, down from $50.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $346.6 million in Q4 2022 and bottomed at $46.6 million in Q3 2025.
  • Average Total Non-Current Liabilities over 4 years is $192.6 million, with a median of $199.4 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities dropped 6.56% in 2023, then tumbled 72.7% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $346.6 million in 2022, then fell by 29.22% to $245.3 million in 2023, then tumbled by 52.36% to $116.9 million in 2024, then tumbled by 60.16% to $46.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CTMX at $46.6 million in Q3 2025, $50.9 million in Q2 2025, and $69.3 million in Q1 2025.